[Retracted] Prognosis and Therapeutic Efficacy Prediction of Adrenocortical Carcinoma Based on a Necroptosis-Associated Gene Signature

Table 1

Basic clinical features of cohorts enrolled in the current study.

	TCGA_ACC ()	GSE19750 ()	GSE33371 ()	GSE49278 ()	Total ()
Gender
Female	47 (60.3%)	11 (50.0%)	16 (69.6%)	36 (81.8%)	110 (65.9%)
Male	31 (39.7%)	11 (50.0%)	7 (30.4%)	8 (18.2%)	57 (34.1%)
Age
Mean (SD)	46.7 (15.9)	52.5 (14)	43 (16.8)	45.1 (17.2)	46.5 (16.2)
Median [min, max]	49.5 [14,77]	54.6 [23.3,72.1]	45 [10,77]	43.5 [15,81]	48 [10,81]
Stage
Stage I	9 (11.5%)	1 (4.5%)	2 (8.7%)	4 (9.1%)	16 (9.6%)
Stage II	37 (47.4%)	7 (31.8%)	10 (43.5%)	24 (54.5%)	78 (46.7%)
Stage III	16 (20.5%)	1 (4.5%)	3 (13.0%)	2 (4.5%)	22 (13.2%)
Stage IV	14 (17.9%)	4 (18.2%)	8 (34.8%)	13 (29.5%)	39 (23.4%)
Unknown	2 (2.6%)	9 (40.9%)		1 (2.3%)	12 (7.2%)
Side
Left	44 (56.4%)		10 (43.5%)	23 (52.3%)	77 (46.1%)
Right	34 (43.6%)		10 (43.5%)	21 (47.7%)	65 (38.9%)
Unknown		22 (100.0%)	3 (13.0%)		25 (15.0%)